Overview

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of the research study drugs nivolumab, ipilimumab, lomustine, bevacizumab, and temozolomide when used following surgery and before standard therapy with radiation and temozolomide in patients with newly diagnosed high grade glioma. Additional aims of the study are to: - Find out side effects (good and bad) of study drug combinations. - Evaluate any preliminary evidence of anticancer activity of study drug combinations . - Evaluate tumor characteristics by collecting brain tumor tissue samples. - Measure the amount of nivolumab and ipilimumab in biospecimens. - Look at biomarkers in biospecimens.
Phase:
Phase 1
Details
Lead Sponsor:
John Wayne Cancer Institute
Treatments:
Antibodies, Monoclonal
Bevacizumab
Dacarbazine
Ipilimumab
Lomustine
Nivolumab
Temozolomide